CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
biopsy alone in diagnosing subjects with clinically significant prostate cancer with MRI visible lesions. This study will consist o...
New York, New York, United States and 2 other locations
and docetaxel in patients with newly metastatic, hormone-sensitive prostate cancer (mHSPC), using a primary endpoint of undetectabl...
Phase 2
New York, New York, United States
study is a randomized study that compares 5 radiation therapy treatments to 2 radiation therapy treatments in men with low or intermediate-risk prostate...
Phase 2
New York, New York, United States and 1 other location
of this study is to evaluate the safety, tolerability, and antitumour activity of AZD0754 CAR T-cell therapy in participants with metastatic prostate...
Phase 1, Phase 2
New York, New York, United States and 14 other locations
This is a phase 1 study to assess the safety and tolerability of ARX517 as monotherapy or combination therapy in adult subjects with metastatic prostate...
Phase 1
New York, New York, United States and 11 other locations
in men with biopsy-proven, low-risk or favorable intermediate-risk prostate cancer managed with active surveillance. The study aims...
Phase 2
New York, New York, United States
and with darolutamide in men with metastatic castration-resistant prostate cancer. The study aims to assess whether the drug is saf ...
Phase 1
New York, New York, United States and 12 other locations
the UroNav software and DynaCAD software for planning and treating prostate cancer as an add on to the already approved workflow of...
New York, New York, United States and 2 other locations
purpose of this study is to assess the safety, tolerability, and preliminary efficacy of BMS-986460 in men with Metastatic Castration-resistant Prostate...
Phase 1
New York, New York, United States and 6 other locations
The main purpose of this study is to assess the safety and tolerability of AZD0516 as monotherapy and/or in combination with other anti-cancer...
Phase 1, Phase 2
New York, New York, United States and 50 other locations
Clinical trials
Research sites
Resources
Legal